evidencegaps
Primary study · included by 1 review

Prevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis.

Peng 2022 · Peng Siyu, Ying Ariel Fangting, Chan Nicholas Jian Hao, et al. · Frontiers in oncology · 2022

Included by

The Efficacy and Safety of Nutritional Supplements for Cancer Supportive Care: An Umbrella Review and Hierarchical Evidence Synthesis.
Non-Cochrane · umbrella · 2026 · cited as Peng 2022 · Reference 72; Tables 2-8
Outcome this study informsPooled effectEvidenceCertainty
Oxaliplatin-induced peripheral neuropathy severity, grade 2 or higher (CTCAE)
N-acetylcysteine (1200 mg/d) vs Placebo
RR 0.26 [0.12, 0.56]2 studies · 46 participantsModerate
Oxaliplatin-induced peripheral neuropathy severity, grade 2 or higher (CTCAE)
L-carnosine (500 to 1000 mg/d) vs Non-active intervention
RR 0.05 [0.01, 0.22]2 studies · 121 participantsLow

1 including review in total.